Time for my annual review of the Fortune 500 list. Every year, this is one of my most popular posts, because it helps us follow the dollar and understand how drug channel intermediaries make money. Our analysis also provides crucial background for understanding the Trump administration’s drug pricing blueprint.
- Drug Rebates Do Not Increase Costs to Consumers
- Trump officials meet with drug companies to push for voluntary price cuts